India, May 25 -- Mumbai-based HAB Pharma aims to scale its revenues to Rs 2,500-3,000 crore by 2030, driven by expanded manufacturing capacity, strengthened R&D capabilities, and a focus on off-patent molecules and complex dosage forms.

The company continues to build on its legacy of providing affordable, high-quality medicines, particularly for general practitioners in India, while enhancing its presence in international markets.

HAB Pharma and Signature Phytochemicals have completed a strategic merger through a slump sale, bringing both companies under a single consolidated entity. Finalised in March 2026, the merger was undertaken to streamline operations, harmonize corporate systems, and strengthen governance, positioning the combin...